Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053436 · ClinicalTrials.gov registry record · Phase 2
Horizon Two: HR NDMM (MMRC-100)
A Phase 2 study, sponsored by Multiple Myeloma Research Consortium.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
NCT07053436: Recruiting Phase 2 study, sponsored by Multiple Myeloma Research Consortium.
NCT07053436 is a Phase 2 study that is actively recruiting participants, run by Multiple Myeloma Research Consortium. The registered enrollment target is 300 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07053436, a Phase 2 study, is actively recruiting participants, sponsored by Multiple Myeloma Research Consortium.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
Study Summary
The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.
Primary Outcome
Sustained MRD negativity is defined as MRD negativity at a minimum threshold of one myeloma cell in one hundred thousand nucleated bone marrow cells at MRD assessments
Interventions
- DRUG Bispecific Monoclonal Antibody and Triplet Therapy
- DRUG Monoclonal Antibody with Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2035-10-12 |
| Phase | Phase 2 |
What NCT07053436 shows while recruiting
NCT07053436 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 2 interventions - of which Bispecific Monoclonal Antibody and Triplet Therapy is the first listed.
NCT07053436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07053436 about?
NCT07053436 is a clinical study titled "Horizon Two: HR NDMM (MMRC-100)". The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient...
What is the current status of trial NCT07053436?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2026-04-30. Estimated completion is 2035-10-12.
What interventions are being tested in trial NCT07053436?
The interventions under investigation include: Bispecific Monoclonal Antibody and Triplet Therapy (DRUG), Monoclonal Antibody with Stem Cell Transplant (DRUG).
Who is sponsoring clinical trial NCT07053436?
This trial is sponsored by Multiple Myeloma Research Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07053436's enrollment target sits among peer trials
300 167th of 2000 higher than 1,813 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI